Abstract
The induction of immune tolerance towards self-antigens presents as a viable future strategy in the treatment of auto-immune diseases, including vasculitis and multiple sclerosis (MS). As specific targets are currently lacking for vasculitis due to incomplete understanding of the pathologies underlying this disease, current treatment options are based on modalities that induce general immune suppression. However, many immune suppressants used in the clinic are known to display wide biodistribution and are thus often accompanied by several adverse effects. Nano-vehicles (NVs) possess the ability to overcome such limitations by enabling more specific delivery of their content through modifications with targeting moieties. In this review, we describe the latest insights in the pathology of vasculitis that may function as potential targets for NV carrier systems, allowing more specific delivery of currently used immune suppressants. In addition, we describe the existing strategies to induce artificial immune tolerance and explore the feasibility of inducing regulatory T cell (Treg) mediated tolerance for MS, possibly mediated by NVs.
Keywords: Nano-vehicle, nanoparticle, vasculitis, multiple sclerosis, drug delivery, targeting, drug release, immune suppressive drugs, nanomedicine, glucocorticosteroids.
Current Pharmaceutical Design
Title:The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis
Volume: 23 Issue: 13
Author(s): R. Huis In ’t Veld, C.G. Da Silva, E.L. Kaijzel, A.B. Chan and L.J. Cruz*
Affiliation:
- Translational Nanobiomaterials and Imaging, Department of Radiology, Leiden University Medical Center, Leiden,Netherlands
Keywords: Nano-vehicle, nanoparticle, vasculitis, multiple sclerosis, drug delivery, targeting, drug release, immune suppressive drugs, nanomedicine, glucocorticosteroids.
Abstract: The induction of immune tolerance towards self-antigens presents as a viable future strategy in the treatment of auto-immune diseases, including vasculitis and multiple sclerosis (MS). As specific targets are currently lacking for vasculitis due to incomplete understanding of the pathologies underlying this disease, current treatment options are based on modalities that induce general immune suppression. However, many immune suppressants used in the clinic are known to display wide biodistribution and are thus often accompanied by several adverse effects. Nano-vehicles (NVs) possess the ability to overcome such limitations by enabling more specific delivery of their content through modifications with targeting moieties. In this review, we describe the latest insights in the pathology of vasculitis that may function as potential targets for NV carrier systems, allowing more specific delivery of currently used immune suppressants. In addition, we describe the existing strategies to induce artificial immune tolerance and explore the feasibility of inducing regulatory T cell (Treg) mediated tolerance for MS, possibly mediated by NVs.
Export Options
About this article
Cite this article as:
In ’t Veld Huis R. , Silva Da C.G. , Kaijzel E.L. , Chan A.B. and Cruz L.J. *, The Potential of Nano-Vehicle Mediated Therapy in Vasculitis and Multiple Sclerosis, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666161221151900
DOI https://dx.doi.org/10.2174/1381612822666161221151900 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Differential Developmental Origin of Arteries: Impact on Angiogenesis and Arteriogenesis
Medicinal Chemistry Reviews - Online (Discontinued) PPARγ and Early Human Placental Development
Current Medicinal Chemistry Editorial: Cocaine and Acute Basilar Artery Occlusion: What we Know to Date?
Current Vascular Pharmacology Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Recent Advance in Aminopeptidase N (APN/CD13) Inhibitor Research
Current Medicinal Chemistry The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Nitrofurantoin Pulmonary Toxicity: Neglected Threat
Current Drug Safety Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Proinflammatory Activities of Leptin in Non-Autoimmune Conditions
Inflammation & Allergy - Drug Targets (Discontinued) Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial
Current Rheumatology Reviews Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design